MGNXMACROGENICS INC

Nasdaq macrogenics.com


$ 3.94 $ 0.56 (16.57 %)    

Monday, 13-May-2024 11:13:08 EDT
QQQ $ 443.34 $ -0.07 (-0.02 %)
DIA $ 395.63 $ -0.75 (-0.19 %)
SPY $ 521.30 $ -1.27 (-0.24 %)
TLT $ 90.41 $ 0.08 (0.09 %)
GLD $ 216.28 $ -0.90 (-0.41 %)
$ 3.31
$ 3.38
$ 3.96 x 200
$ 4.19 x 100
$ 3.38 - $ 4.13
$ 3.14 - $ 21.88
34,882,938
na
206.18M
$ 1.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-07-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-02-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-02-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-04-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-06-2015 03-31-2015 10-Q
38 03-03-2015 12-31-2014 10-K
39 11-12-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-macrogenics-lowers-price-target-to-14

Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $25 to ...

 macrogenics-gets-downgraded-following-disappointing-prostate-cancer-trial-results-we-were-surprised-by-reported-deaths

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

 stocks-pause-on-dismal-consumer-confidence-yields-dollar-rise-as-inflation-expectations-kick-higher-bitcoin-sinks-whats-driving-markets-friday-corrected

Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.

 jmp-securities-maintains-market-outperform-on-macrogenics-lowers-price-target-to-16

JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price tar...

 bmo-capital-downgrades-macrogenics-to-market-perform-lowers-price-target-to-8

BMO Capital analyst Etzer Darout downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform and lowers the price...

 macrogenics-shares-tumble-after-reporting-adverse-events-multiple-deaths-in-cancer-drug-trial

Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 ...

 td-cowen-downgrades-macrogenics-to-hold

TD Cowen analyst Boris Peaker downgrades Macrogenics (NASDAQ:MGNX) from Buy to Hold.

 stifel-downgrades-macrogenics-to-hold-lowers-price-target-to-7

Stifel analyst Stephen Willey downgrades Macrogenics (NASDAQ:MGNX) from Buy to Hold and lowers the price target from $29 to $7.

 macrogenics-q1-2024-gaap-eps-084-misses-061-estimate-sales-9104m-miss-14617m-estimate

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.61)...

 td-cowen-upgrades-macrogenics-to-buy

TD Cowen analyst Boris Peaker upgrades Macrogenics (NASDAQ:MGNX) from Hold to Buy.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION